viewArgo Blockchain PLC

Investor Update: Argo Blockchain agrees deal to expand electricity supply by 357%

Headlines from the Proactive UK newsroom.

Argo Blockchain (LON:ARB) is to boost its electricity supply by 357% through a deal with a leading Canadian data centre provider. Argo now has access to 64 megawatts of electricity for bitcoin mining.

Bacanora Lithium PLC (LON:BCN) has received the second approval of the three required for an investment by Chinese firm Ganfeng. The final approval will be received following a Ganfeng board meeting in the coming weeks. 

Ironridge Resources (LON:IRR) has produced a high-grade source of lithium from ore mined at its project in Ghana. Work is now underway to convert the concentrate into higher value lithium hydroxide. 

ARC Minerals (LON:ARCM) has unearthed more high grade copper indications at shallow depths at Cheyeza East in Zambia. The mineralised zone now extends to a width of 300m with a strike of 650m.

Persimmon’s decision to invest in improving the quality of its houses hit its first half numbers. Revenues dipped 4.5% while the number of completions fell 6%.

Mining giant BHP paid out a record final dividend as it topped up the expected amount by a further US$1.3bn. Underlying annual profits rose by 2% to US$9.1bn.

An AstraZeneca drug has shown a significant improvement in people already under treatment for heart failure. Farxiga significantly reduced the risk of cardiovascular death when added to the standard of care treatment.

Quick facts: Argo Blockchain PLC

Price: 4.55 GBX

Market: LSE
Market Cap: £13.37 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Argo Blockchain PLC named herein, including the promotion by the Company of Argo Blockchain PLC in any Content on the Site, the Company...



Shield Therapeutics CEO says all efforts are on securing US partner for Feraccru

Shield Therapeutics PLC’s (LON:STX) chief executive Tim Watts caught up with Proactive's Andrew Scott on the back of its 2019 results. He says that finding a US partner for its iron deficiency drug Accrufer is the top priority for 2020. Shield already has commercial agreements in Europe...

3 days, 11 hours ago

2 min read